375 related articles for article (PubMed ID: 26015407)
1. Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases.
Lamora A; Mullard M; Amiaud J; Brion R; Heymann D; Redini F; Verrecchia F
Oncotarget; 2015 Jun; 6(16):14413-27. PubMed ID: 26015407
[TBL] [Abstract][Full Text] [Related]
2. Halofuginone inhibits the establishment and progression of melanoma bone metastases.
Juárez P; Mohammad KS; Yin JJ; Fournier PG; McKenna RC; Davis HW; Peng XH; Niewolna M; Javelaud D; Chirgwin JM; Mauviel A; Guise TA
Cancer Res; 2012 Dec; 72(23):6247-56. PubMed ID: 23002206
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma.
Lamora A; Talbot J; Bougras G; Amiaud J; Leduc M; Chesneau J; Taurelle J; Stresing V; Le Deley MC; Heymann MF; Heymann D; Redini F; Verrecchia F
Clin Cancer Res; 2014 Oct; 20(19):5097-112. PubMed ID: 25107916
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor necrosis factor therapy inhibits lung metastasis in an osteosarcoma cell line.
Kato H; Wakabayashi H; Naito Y; Kato S; Nakagawa T; Matsumine A; Sudo A
Oncology; 2015; 88(3):139-46. PubMed ID: 25402182
[TBL] [Abstract][Full Text] [Related]
5. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling.
Gnainsky Y; Kushnirsky Z; Bilu G; Hagai Y; Genina O; Volpin H; Bruck R; Spira G; Nagler A; Kawada N; Yoshizato K; Reinhardt DP; Libermann TA; Pines M
Cell Tissue Res; 2007 Apr; 328(1):153-66. PubMed ID: 17180598
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
7. TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.
Moukengue B; Brown HK; Charrier C; Battaglia S; Baud'huin M; Quillard T; Pham TM; Pateras IS; Gorgoulis VG; Helleday T; Heymann D; Berglund UW; Ory B; Lamoureux F
EBioMedicine; 2020 Mar; 53():102704. PubMed ID: 32151797
[TBL] [Abstract][Full Text] [Related]
8. The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
Koshkina N; Yang Y; Kleinerman ES
Adv Exp Med Biol; 2020; 1258():177-187. PubMed ID: 32767242
[TBL] [Abstract][Full Text] [Related]
9. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.
Sampson ER; Martin BA; Morris AE; Xie C; Schwarz EM; O'Keefe RJ; Rosier RN
J Bone Miner Res; 2011 Jun; 26(6):1283-94. PubMed ID: 21308771
[TBL] [Abstract][Full Text] [Related]
10. Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model.
Scharf VF; Farese JP; Siemann DW; Abbott JR; Kiupel M; Salute ME; Milner RJ
Anticancer Drugs; 2014 Mar; 25(3):332-9. PubMed ID: 24304691
[TBL] [Abstract][Full Text] [Related]
11. Anti-Metastatic Properties of a Marine Bacterial Exopolysaccharide-Based Derivative Designed to Mimic Glycosaminoglycans.
Heymann D; Ruiz-Velasco C; Chesneau J; Ratiskol J; Sinquin C; Colliec-Jouault S
Molecules; 2016 Mar; 21(3):309. PubMed ID: 26959001
[TBL] [Abstract][Full Text] [Related]
12. The Anthelmintic Drug Niclosamide Inhibits the Proliferative Activity of Human Osteosarcoma Cells by Targeting Multiple Signal Pathways.
Liao Z; Nan G; Yan Z; Zeng L; Deng Y; Ye J; Zhang Z; Qiao M; Li R; Denduluri S; Wang J; Wei Q; Geng N; Zhao L; Lu S; Wang X; Zhou G; Luu HH; Haydon RC; He TC; Wang Z
Curr Cancer Drug Targets; 2015; 15(8):726-38. PubMed ID: 26118906
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway.
Hou CH; Lin FL; Tong KB; Hou SM; Liu JF
Biochem Pharmacol; 2014 Jun; 89(4):453-63. PubMed ID: 24685520
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
[TBL] [Abstract][Full Text] [Related]
15. Effect of halofuginone on the inhibition of proliferation and invasion of hepatocellular carcinoma HepG2 cell line.
Huo S; Yu H; Li C; Zhang J; Liu T
Int J Clin Exp Pathol; 2015; 8(12):15863-70. PubMed ID: 26884857
[TBL] [Abstract][Full Text] [Related]
16. Halofuginone ameliorates autoimmune arthritis in mice by regulating the balance between Th17 and Treg cells and inhibiting osteoclastogenesis.
Park MK; Park JS; Park EM; Lim MA; Kim SM; Lee DG; Baek SY; Yang EJ; Woo JW; Lee J; Kwok SK; Kim HY; Cho ML; Park SH
Arthritis Rheumatol; 2014 May; 66(5):1195-207. PubMed ID: 24782183
[TBL] [Abstract][Full Text] [Related]
17. PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma.
Ek ET; Dass CR; Contreras KG; Choong PF
J Orthop Res; 2007 Dec; 25(12):1671-80. PubMed ID: 17600821
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
Elkin M; Reich R; Nagler A; Aingorn E; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Clin Cancer Res; 1999 Aug; 5(8):1982-8. PubMed ID: 10473075
[TBL] [Abstract][Full Text] [Related]
19. STAT3 activation by IL-6 from mesenchymal stem cells promotes the proliferation and metastasis of osteosarcoma.
Tu B; Du L; Fan QM; Tang Z; Tang TT
Cancer Lett; 2012 Dec; 325(1):80-8. PubMed ID: 22743617
[TBL] [Abstract][Full Text] [Related]
20. S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: therapeutic and diagnostic clinical applications.
Parashar S; Cheishvili D; Arakelian A; Hussain Z; Tanvir I; Khan HA; Szyf M; Rabbani SA
Cancer Med; 2015 May; 4(5):732-44. PubMed ID: 25619880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
